Latest papers

Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.

Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.

Chemoenzymatic synthesis of small molecule human therapeutics.

[New role for tobacco--production of biopharmaceuticals].

[Toxicological evaluation of biopreparations on the basis of nitrogen-fixing bacteria].

Do physicians' beliefs about genetic engineering influence their likelihood of prescribing a biopharmaceutical? An empirical investigation.

Pharmacovigilance of biopharmaceuticals: challenges remain.

BCS in drug discovery, development, and regulation.

Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class.

Deborah Dunsire.

Drug discovery: past, present and future.

Antibodies and other biopharmaceuticals.

Drug absorption modeling as a tool to define the strategy in clinical formulation development.

Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.

A bayesian approach for quantifying trace amounts of antibody aggregates by sedimentation velocity analytical ultracentrifugation.

Determination of log D via automated microfluidic liquid-liquid extraction.

Characterization and activity of cephalosporin metal complexes.

Current legal, regulatory, and scientific implications of biosimilars. Introduction.

Biosimilars: illustration of scientific issues in two examples.

Biosimilars: policy, clinical, and regulatory considerations.